Changes in aerobic capacity were evaluated after 12 weeks of training among a motivated heterogeneous group of cancer survivors (N = 54 [41 women and 13 men]), living at moderate altitude. Changes in power at lactate threshold (PT(lact)), peak power (P(peak)), and peak oxygen uptake (VO(2) peak) were evaluated in this group (average age, 53.8 + or - 10.8 years) that completed a minimum of 12 weeks of an individualized exercise program (on average 5 days x week(-1) for 47.5 + or - 17.2 min x session(-1)). Daily exercise duration was based on the goals and functional capacity of each individual. Training intensity for each subject was based on heart rate (HR) value at lactate threshold (T(lact)) obtained during a symptom-limited cardiopulmonary exercise test. Intensity was categorized into 5 ranges: recovery (60%-80% HR T(lact)); endurance (80%-100% HR T(lact)); threshold (100%-105% HR T(lact)); intervals (105%-115% HR T(lact)); and maximal efforts (> or = 115% HR T(lact)). Overall compliance with the exercise prescription was approximately 72% and subjects reported exercising within the 5 training ranges, 12.1%, 63.9%, 18.6%, 4.2%, and 1.2% of the time, respectively. After training, PT(lact) increased 9.5% (121.8 + or - 43.5 vs 133.2 + or - 34.1 W; P < 0.05), P(peak) increased 12.6% (175.5 + or - 55.6 vs 195.6 + or - 54.2 W; P < 0.05) and VO(2) peak increased 11.4% (33.4 + or - 12.5 vs 37.2 + or - 10.4 mL x kg(-1) x min(-1); P < 0.05). The results of this research indicate that: 1) cardiopulmonary exercise testing with lactate threshold determination was safe and effective in the evaluation and exercise prescription phase for a group of cancer survivors and 2) a training program based on 2 higher intensity workouts per week can elicit significant changes in aerobic capacity of a diverse group of cancer survivors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3810/psm.2009.10.1731 | DOI Listing |
JCO Oncol Pract
January 2025
Mayo Clinic, Department of Internal Medicine, Division of Oncology, Rochester, MN.
Purpose: Over 50% of households in the United States have at least one musician-many musicians are also breast cancer survivors. This group has not been well studied, and given the level of fine sensory-motor skill required for musicianship, we hypothesized that musicians experience unique manifestations of breast cancer treatment toxicities.
Methods: A nine-item Musical Toxicity Questionnaire (MTQ) was distributed to patients who had consented to participate in the Mayo Clinic Breast Cancer Registry.
PLoS One
January 2025
Researching in Sport Science: Research Group (CTS-563) of the Andalusian Research Plan, University of Malaga, Malaga, Spain.
The purpose of this longitudinal study was to determine the effects of a rowing training program on physical fitness and body composition in female breast cancer survivors (56.78 ± 6.38 years).
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Division of Hematology, Oncology, and Transplantation, University of Minnesota Twin Cities, Minneapolis.
Proc Natl Acad Sci U S A
January 2025
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Ependymoma (EPN) is a common form of brain tumor in children, often resistant to available cytotoxic therapies. Molecular profiling studies have led to a better understanding of EPN subtypes and revealed a critical role of oncogenes ZFTA-RELA fusion and EPHB2 in supratentorial ependymoma (ST-EPN). However, the immune system's role in tumor progression and response to therapy remains poorly understood.
View Article and Find Full Text PDFIntroduction: As pharmacological strategies remain limited for relieving fatigue and associated cognitive symptoms, integrative modalities such as traditional Chinese medicine (TCM) could be explored as therapeutic strategies in cancer survivors. Here, we evaluate and report the efficacy and safety of a TCM concoction, modified Xiang Bei Yang Rong Tang (XBYRT), on quality of life (QOL), cancer-related fatigue (CRF), and cognitive symptoms, compared to placebo.
Methods: In a single-centered, randomized, double-blinded, placebo-controlled pilot trial conducted from 2019 to 2022, fatigued cancer survivors ≥21 years old were recruited to receive the XBYRT intervention or placebo (5% diluted) once daily for the duration of 8 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!